Showing 5601-5610 of 9400 results for "".
- Lilly: Taltz Tops Adalimumab for PsA in Head-to-Headhttps://practicaldermatology.com/news/lilly-taltz-tops-adalimumab-for-psa-in-head-to-head/2460069/Results of the phase 3b/4 SPIRIT-Head-to-Head (H2H) study in patients with active psoriatic arthritis (PsA), presented as a late-breaking abstract at the European Congress of Rheumatology (EULAR) in Madrid, show that a significantly higher proportion of patients met the primary end
- Novartis: New Data Show Cosentyx Has Durable Response Across Psoriatic Diseasehttps://practicaldermatology.com/news/novartis-new-data-show-cosentyx-has-durable-response-across-psoriatic-disease/2460068/A new comprehensive analysis shows the long-term efficacy and safety of secukinumab in multiple manifestations of psoriatic disease, including moderate-to-severe plaque-type, nail and palmoplantar psoriasis, psoriatic arthritis and ankylosing spondylitis. Data are derived from key Phase 3, random
- Aclaris Therapeutics: Positive 6-Month Results from Phase 2 Open-Label Trial of Topical ATI-502 in Androgenetic Alopeciahttps://practicaldermatology.com/news/aclaris-therapeutics-positive-6-month-results-from-phase-2-open-label-trial-of-topical-ati-502-in-androgenetic-alopecia/2460067/Results from a Phase 2 open-label clinical trial of ATI-502 (AGA-201), an investigational topical Janus Kinase (JAK) 1/3 inhibitor are promising for patients with androgenetic alopecia (AGA). Aclaris Therapeutics announced the findings and says 12-month data should be available by year’s en
- Lilly: 5-Year Sustained Efficacy and Safety Results for Taltz in Plaque Psoriasis at WCDhttps://practicaldermatology.com/news/lilly-5-year-sustained-efficacy-and-safety-results-for-taltz-in-plaque-psoriasis-at-wcd/2460066/Patients with moderate- to severe plaque psoriasis who continued to receive Taltz® (ixekizumab) maintained high levels of skin clearance with no unexpected safety outcomes for up to five years of treatment, according to new data Eli Lilly and Company is presenting at the World Congress of Der
- Skin Metabolomics: Estee Lauder Presents New Research at WCDhttps://practicaldermatology.com/news/skin-metabolomics-estee-lauder-presents-new-research-at-wcd/2460063/The Estée Lauder Companies Inc.Research & Development (R&D) team will present data focused on new findings in skin metabolomics, skin defense, ingredient science, and anti-aging research at the 2019 World Congress of Dermatology (WCD) in Milan, Italy from June 10 -15.
- Burt's Bees Data at WCD Highlights Power of Naturalshttps://practicaldermatology.com/news/burts-bees-data-at-wcd-highlights-power-of-naturals/2460062/New research from Burt's Bees supports findings related to the skin's composition and the role of nature-based regimens to protect the skin against common environmental stressors. The studies will be presented at the 24th World Congress of Dermatology (WCD) Meeting in Milan
- Derm Residents Optimize Total Skin Exams Using Bioengineering Principleshttps://practicaldermatology.com/news/derm-residents-optimize-total-skin-exams-using-bioengineering-principles/2460058/Researchers at the Penn State Health Milton S. Hershey Medical Center are using engineering principles to improve the accuracy and efficiency of total body skin exams. There is no standardized method for performing a total body skin exam. D
- Pivotal Phase 3 Trials of Trifarotene in Patients with Moderate Facial and Truncal Acne Meet All Efficacy Endpointshttps://practicaldermatology.com/news/pivotal-phase-3-trials-of-trifarotene-in-patients-with-moderate-facial-and-truncal-acne-meet-all-efficacy-endpoints-2/2460056/Results from the pivotal Phase 3 PERFECT 1 and PERFECT 2 clinical trials of once-daily trifarotene 50 µg/g cream in patients with moderate acne on the face and trunk, published in the June issue of Journal of the American Academy of Dermatology, met all primary and secondary efficacy endpoi
- Sciton Promotes Two Leadershttps://practicaldermatology.com/news/sciton-promotes-two-leaders/2460050/Bryant Wong is the new Vice President of Finance at Sciton and Emma Haaland is the new Global Director of Customer Service. Mr. Wong spent two years as the leader of the finance department at Sciton. He worked for nearly 12 years with PricewaterhouseCoopers and Deloitte C
- New NRS Study Shows Positive Impact of Clear Skin in Rosacea Patientshttps://practicaldermatology.com/news/new-nrs-study-shows-positive-impact-of-clear-skin-in-rosacea-patients/2460048/Treating rosacea can have a major positive impact on patients’ lives, according to a new survey by the National Rosacea Society. In the survey of 1,044 rosacea patients, around 76 percent of all respondents saw at least some improvement in th